Hosted By
In today’s episode, Dinkar Sindhu, CEO of Axis Clinicals, dives into the world of clinical research and the cautious integration of AI in drug development.
From testing groundbreaking GLP-1 drugs like Ozempic to navigating the complexities of FDA approvals, Dinkar reveals the meticulous process behind ensuring that new drugs are safe and effective.
“AI can help, but it must be traceable and reproducible,” he explains, sharing lessons from a pilot program where inconsistent AI outputs raised red flags.
Join us for an insightful look at how clinical trials shape the future of medicine, the challenges of AI in ensuring data integrity, and why human oversight remains vital.
In 2019, a team at Google led by physicist John Martinis achieved something once thought impossible—a quantum processor completed in three minutes a calculation...
In today’s episode, author Jack Bialik joins us to explore the mysteries of lost civilizations and forgotten knowledge behind his book Lost in Time....
The Iran conflict isn't just a Middle East story — it's a financial war with consequences for every American's wallet. In this episode of...
